Skip to main content

Table 1 Demographic and clinical characteristics of patients with COVID-19

From: Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study

 

Total (n = 70)

Non-ICU (n = 30)

ICU (n = 23)

Fatality (n = 17)

Age, years

56.5 (41–73)

46 (31–65.5)

57 (44–66)

73 (63–79)

Sex, Male

46 (65.7)

20 (66.7)

13 (56.5)

13 (76.5)

Viral shedding period, days

12 (9–16.3)

9 (6–11.3)

13 (11–16)

19 (12.5–21)a

Chronic comorbidities

 Hypertension

18 (25.7)

8 (26.7)

7 (30.4)

3 (17.6)

 Diabetes

13 (18.6)

3 (10)

5 (16.7)

5 (29.4)

 Cardiovascular diseases

7 (10)

2 (6.7)

3 (13)

2 (11.8)

 Chronic kidney disease

4 (5.7)

20

3 (13)

1 (5.9)

 Respiratory system diseases

1 (1.4)

0 (0)

0 (0)

1 (5.9)

Chronic liver diseases

13 (18.6)

6 (20)

5 (16.7)

2 (11.8)

 Chronic hepatitis B

5 (7.1)

1 (3.3)

3 (13)

1 (5.9)

 Alcoholic liver disease

5 (7.1)

5 (16.7)

0 (0)

0 (0)

 Fatty liver disease

2 (2.9)

0 (0)

1 (4.3)

1 (5.9)

 Chronic hepatitis C

1 (1.4)

0 (0)

1 (4.3)

0 (0)

HBV markers

    

 HBsAg/HBeAb/HBcAb (+)

5 (7.1)

1 (3.3)

3 (13)

1 (5.9)

 HBsAb/HBeAb/HBcAb (+)

38 (54.3)

10 (33.3)

15 (65.2)

13 (76.5)

 All HBV markers (−)

11 (15.7)

6 (20)

3 (13)

2 (11.8)

 Sole HBsAb (+)

7 (10)

6 (20)

0 (0)

1 (5.9)

 Sole HBcAb (+)

4 (5.7)

3 (10)

1 (4.3)

0 (0)

 HBeAb/HBcAb (+)

3 (4.3)

2 (6.7)

1 (4.3)

0 (0)

 HBsAb/HBcAb (+)

2 (2.9)

2 (6.7)

0 (0)

0 (0)

Self-medication after illness

22 (31.4)

8 (26.7)

6 (26.1)

8 (47.1)

 Traditional Chinese medicine

14 (20)

6 (6.7)

4 (17.4)

4 (23.5)

 Acetaminophen

4 (5.7)

2 (6.7)

1 (4.3)

1 (5.9)

 Levofloxacin/Moxifloxacin

4 (5.7)

0 (0)

1 (4.3)

3 (17.6)

Treatment during hospitalization

    

 Symptomatic treatment

62 (88.6)

22 (73.3)

23 (100)

17 (100)

 Antiviralsb

56 (80)

20 (66.7)

19 (82.6)

17 (100)

 Antibioticsc

36 (51.4)

8 (26.7)

11 (47.8)

17 (100)

 Traditional Chinese medicine

12 (17.1)

3 (10)

5 (21.7)

4 (23.5)

 Immunoglobulin

20 (28.6)

0 (0)

7 (30.4)

13 (76.5)

 Glucocorticoid

17 (24.3)

0 (0)

5 (21.7)

12 (70.6)

 High-flow oxygen

35 (50)

0 (0)

18 (78.3)

17 (100)

 Mechanical ventilation

17 (24.3)

0 (0)

3 (13)

14 (82.4)

 CRRT

11 (15.7)

0 (0)

0 (0)

11 (64.7)

  1. Data are presented as median (interquartile range) or n (%)
  2. aThe viral shedding period in the fatality group was calculated from the beginning of detectable SARS-CoV-2 to the discontinuation of viral shedding or to the death date, even though viral shedding continued at the time of fatality
  3. bAntiviral agents mainly included oseltamivir, interferon α (aerosol inhalation), and lopinavir/ritonavir
  4. cAntibiotics mainly included levofloxacin and moxifloxacin for all groups and meropenem, biapenem, vancomycin, and tigecycline for the fatality group
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us